About Enyo Pharma
Enyo Pharma is a company based in Lyon (France) founded in 2014.. Enyo Pharma has raised $120.34 million across 8 funding rounds from investors including Orbimed, Bpifrance and Andera Partners. Enyo Pharma offers products and services including Vonafexor. Enyo Pharma operates in a competitive market with competitors including NGM Biopharmaceuticals, Nimbus Therapeutics, Mirum Pharmaceuticals, Madrigal Pharmaceuticals and Akero Therapeutics, among others.
- Headquarter Lyon, France
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Enyo Pharma Sa
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$120.34 M (USD)
in 8 rounds
-
Latest Funding Round
$6.87 M (USD), Series C
Jun 12, 2025
-
Investors
Orbimed
& 9 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Enyo Pharma
Enyo Pharma offers a comprehensive portfolio of products and services, including Vonafexor. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Small molecule treating kidney diseases like Alport Syndrome
Unlock access to complete
Unlock access to complete
Funding Insights of Enyo Pharma
Enyo Pharma has successfully raised a total of $120.34M across 8 strategic funding rounds. The most recent funding activity was a Series C round of $6.87 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Series C — $6.9M
- First Round First Round
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2025 | Amount | Series C - Enyo Pharma | Valuation |
investors |
|
| Jan, 2024 | Amount | Series C - Enyo Pharma | Valuation | Orbimed , Morningside | |
| Oct, 2018 | Amount | Grant - Enyo Pharma | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Enyo Pharma
Enyo Pharma has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Bpifrance and Andera Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Multiple sectors are invested in by Morningside, a VC fund.
|
Founded Year | Domain | Location | |
|
Capital is provided to firms for growth, buyouts, and acquisitions.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Enyo Pharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Enyo Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Enyo Pharma Comparisons
Competitors of Enyo Pharma
Enyo Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Nimbus Therapeutics, Mirum Pharmaceuticals, Madrigal Pharmaceuticals and Akero Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| domain | founded_year | HQ Location |
Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for metabolic disorders are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Enyo Pharma
Frequently Asked Questions about Enyo Pharma
When was Enyo Pharma founded?
Enyo Pharma was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Where is Enyo Pharma located?
Enyo Pharma is headquartered in Lyon, France. It is registered at Lyon, Auvergne-rhone-alpes, France.
Is Enyo Pharma a funded company?
Enyo Pharma is a funded company, having raised a total of $120.34M across 8 funding rounds to date. The company's 1st funding round was a Grant of $2.84M, raised on Jun 01, 2015.
What does Enyo Pharma do?
Enyo Pharma was founded in 2014 and is based in Lyon, France. Therapeutics targeting diseases associated with impaired kidney function are developed by the company within the pharmaceutical sector. Operations focus on small molecules such as VONAFEXOR, which exhibits fibrolytic and anti-inflammatory effects in both kidney and liver tissues. The companys activities center on advancing treatments for organ-specific conditions.
Who are the top competitors of Enyo Pharma?
Enyo Pharma's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Madrigal Pharmaceuticals.
What products or services does Enyo Pharma offer?
Enyo Pharma offers Vonafexor.
Who are Enyo Pharma's investors?
Enyo Pharma has 10 investors. Key investors include Orbimed, Bpifrance, Andera Partners, European Union, and Inserm Transfert.